Transdermal scopolamine alters phasic REM activity in normal young adults

Area of Science:

• Neuroscience
• Sleep Medicine
• Pharmacology

Background:

• Transdermal scopolamine is a common anti-motion sickness medication.
• Its effects on sleep physiology, particularly rapid eye movement (REM) sleep, are not well understood.
• Previous studies indicate injectable or oral scopolamine can alter REM sleep architecture.

Purpose of the Study:

• To investigate the impact of transdermal scopolamine on REM sleep.
• To determine if transdermal scopolamine affects REM sleep similar to other administration forms.
• To examine changes in REM sleep variables with a 1.5 mg transdermal scopolamine patch.

Main Methods:

• A double-blind, crossover study involving eight healthy young males.
• Polysomnographic recordings over three nights (including one adaptation night).
• Comparison of REM sleep parameters between nights with scopolamine patch and placebo patch.

Main Results:

• No significant differences were observed in tonic REM sleep measures (duration, latency).
• Phasic REM sleep measures, including total REM activity and REM density, were significantly suppressed.
• Specific reductions in REM density during the first two REM periods and REM activity during the fourth REM period were noted.

Conclusions:

• Transdermal scopolamine at a low dose suppresses phasic REM sleep components.
• Phasic REM sleep measures may serve as sensitive markers of central nervous system cholinergic activity.
• Further research could utilize these markers to assess cholinergic mechanisms.